Jonathan Silverberg, MD, PhD, MPH, examines the significant effects of chronic skin conditions such as atopic dermatitis and prurigo nodularis on patients' well-being, emphasizing the crucial role of prompt diagnosis in managing these impactful dermatologic diseases.
Critical voids in the management of idiopathic pulmonary fibrosis are discussed by Justin Oldham, MD, MS.
The panel explores how IPF affects patient productivity and its contribution to the disease's overall economic burden.
Decision-making factors surrounding optimal IPF treatment selection are evaluated by Justin Oldham, MD, MS.
An expert on idiopathic pulmonary fibrosis describes the therapeutic response of standard-of-care treatments and how multidisciplinary care can be optimized when treating patients.
Justin Oldham, MD, MS, discusses the current standard of car in treating idiopathic pulmonary fibrosis and the role of non-pharmacologic therapies.
Dr Nathan provides his final thoughts regarding IPF management.
Dr Nathan discusses the trajectory of IPF management.
Steven Nathan, MD, continues a discussion surrounding the patient journey in through IPF treatment.
Dr Nathan highlights the role of PDE4B inhibitors in IPF management.
Steven Nathan, MD, discusses breakthrough treatments for idiopathic pulmonary fibrosis.
A health care provider outlines treatment objectives and supportive interventions for managing Friedreich ataxia, addressing associated comorbidities and symptoms in clinical settings.
The panel discusses out of pocket costs and the impact of the 340b program for various patient types.
The panel discusses how employer preferences influence the strategies and decisions of payers/PBMs.
Dr. Cannon discusses payers and PBMs making decisions about biosimilars in the commercial sector.
A panel of experts discuss using systemic corticosteroids in CSU treatment.
A panel of experts discuss switching between different antihistimines and other medications when treating CSU patients.
Stanley Goldstein, MD, discusses which therapies are typically used initially for CSU patients.
A panel of experts discuss the healthcare specialties that become involved in treating patients with CSU.
Key opinion leaders analyze unmet needs and emerging trends in melanoma treatment based on findings presented at ASCO 2024.
In their concluding remarks, the expert panel shares insights and provides recommendations to help practicing clinicians optimize atopic dermatitis patient care.
Reynold A. Panettieri Jr., MD, explores the impact of COPD and asthma on patients' quality of life, highlighting exercise limitations and sleep disturbances.
A panel of experts discuss how the NCCN guideline recommendations differ for patients with and without PD-L1 expression.
A panel of experts describe the key challenges and unmet needs for patients with newly diagnosed mNSCLC.
A leading oncologist explores promising new breast cancer therapies in the drug development pipeline and advises healthcare providers on strategies to remain informed about the most current treatment guidelines and recommendations.
An oncologist specializing in breast cancer treatment reviews the latest guideline recommendations for systemic therapies in HR+/HER2- breast cancer, comparing the available CDK4/6 inhibitors and discussing considerations for optimal treatment sequencing.
Key discussion points for educating patients on infection risk management in PNH care are highlighted.
